+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-09-01Number of Pages: 121

Hospital Infection Therapeutics Market (Drug Type: Antibacterial, Antiviral and Antifungal Drugs; Infection Type: Hospital-Acquired Pneumonia, Urinary Tract Infections, Gastrointestinal Disorders, Bloodstream Infections, Surgical Site Infections and Other Hospital Infections) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Hospital infection is also referred to as healthcare-associated infection (HCAI) or nosocomial infection or hospital-acquired infection (HAI). HAI are those infections that develop in patients undergoing treatment in a healthcare setting, it also includes those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. According to the Centers for Disease Control and Prevention (CDC), in 2011, approximately 1.7 million HAIs from all types of bacteria combined are reported each year in the U.S. In addition, according to the ECDC estimates, in 2013 around 4.1 million patients were diagnosed with HAI in Europe (including 30 nations).
 
Global hospital infection therapeutics market has been classified into three major segments, based on the type of drugs, namely, antibacterial, antiviral and antifungal drugs. In 2013, the antibacterial drugs segment held the largest share (70.7%) in the global hospital infection therapeutics market. Antibacterial drugs segment is also expected to be the fastest growing segment in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. The global hospital infection therapeutics market has been also classified into six major segments, based on the type of major hospital infections, namely, hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. In 2013, the hospital-acquired pneumonia segment held the largest share (over 20%) in the global hospital infection therapeutics market. Urinary tract infections segment is expected to be the fastest growing segment during the forecast period 2014 to 2020.
 
Some of the major driving factors for the growth of this market are increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. Demand for hospital infection therapeutics will especially rise in low to medium income countries due to the presence of high patient population suffering from different hospital infections, hot and humid environmental conditions, lack of standard healthcare facilities and low social awareness. However, rising multi-drug resistant bacterial strains have rendered available drugs obsolete. Moreover, increasing infection control and surveillance programs may present a threat to the growth of this market. Huge scope for the development of hospital infection therapeutics in treating range of multi-drug resistant microbes and increased penetration in emerging economies would contribute to the growth of the market in near future.
 
North America dominates the global hospital infection therapeutics market followed by the European market in 2013. Key factors contributing to the growth of the region are high prevalence of various hospital infections, rising number of multi-drug resistant microbial pathogens, increasing demand for advanced therapeutics, and high ratio of hospitals per thousand of the population. This region also comprises huge geriatric population that are more prone towards different hospital infections due to their lowered immunity levels, hence require use of various antimicrobial therapeutics, which in turn will contribute towards the growth of this market. Asia-Pacific represents the fastest growing geographic region in the global hospital infection therapeutics market during the forecast period from 2014 to 2020. Key factor responsible for the rapid growth of this market is increasing prevalence of hospital-acquired infections in the region. Increasing healthcare awareness and infrastructure along with increasing purchasing power of the people will add to the growth of this market in the region.
 
Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are some of the major players operating in the global hospital infection therapeutics market. Most of these players constantly innovate and develop new, improved and/or advanced therapeutic drugs that cater to a larger audience worldwide to maintain their position in the global market. 

 
Hospital-acquired infections are caused by bacterial, fungal, and viral pathogens. A majority of cases of hospital infections start from the intensive care units (ICUs). A large number of antimicrobial drugs have proven their competence in the treatment of a wide range of hospital infections. 
 
This report predicts and analyzes the market for hospital infection therapeutics, on a regional and global level. The prediction is offered in terms of volume as well as revenue of the hospital infection therapeutics market in the forecasting horizon between 2014 and 2020. This research report includes the factors that fuel the market, as well as the restraining factors that will adversely influence the growth of the market during the forecast horizon.
 
In order to achieve a more crisp understanding of the hospital infection therapeutics market, TMR analysts have demonstrated an in-depth analysis of the value chain of the market. The business methodologies incorporated by the key players in the market are also elaborated in this report. The prominent players in the hospital infection therapeutics market, along with their competitive profiling as well as independent market shares across the four major geographical regions, have been included in this report. To get a know-how of the market dynamics, an evaluation of market attractiveness has also been incorporated in this study.
 
Overview of the Hospital Infection Therapeutics Market
 
The patients undergoing treatments in hospitals can develop infections in the course of their stay in the hospitals. These infections are called as hospital infections or hospital-acquired infections (HAI). These infections spread in healthcare environments such as outpatient surgery centers, rehabilitation centers, dialysis centers, hospitals, and nursing homes.
 
On the basis of the type of drug, the market for hospital infection therapeutics is segmented into antibacterial drugs, antifungal drugs, and antiviral drugs. The antibacterial drugs segment constituted the biggest share – 70.7% – in 2013 in the global market for hospital infection therapeutics. The antibacterial drugs segment is also anticipated to be the most swiftly developing segment in the market for global hospital infection in the forecast horizon from 2014 to 2020.
 
In terms of major types of infections, the market for hospital infection therapeutics is segmented into gastrointestinal disorders, bloodstream infections, hospital-acquired pneumonia (HAP), surgical site infections, urinary tract infections, and other hospital infections. The largest share in the global hospital infection therapeutics market was held by the hospital-acquired pneumonia segment in 2013, which represented more than 20% of the overall market. However, the segment of urinary tract infections is projected to expand at a rapid rate in the coming future.
 
On the basis of geography, the global hospital infection therapeutics market has been segmented into Europe, North America, Asia Pacific, and Rest of the World (RoW). On the basis of revenue, the market for hospital infection therapeutics was led by North America in 2013. After North America, the second biggest regional market was Europe. However, the hospital infection therapeutics market in Asia Pacific is predicted to witness the highest rate of growth throughout the forecast horizon.
 
The increase in the geriatric population, improved healthcare awareness, therapeutic drugs being highly in demand, and high occurrence of hospital infections are the key factors that stimulate the growth of the global hospital infection therapeutics market. Key factors that impede the growth of this market include rise in infection control, soaring number of multidrug-resistant bacterial strains, and hospital surveillance programs in emerging economies, which are leading to a reduced occurrence of hospital infections.
 
Key players in the Hospital Infection Therapeutics Market
 
AstraZeneca plc, Actavis plc, Bayer AG, Cubist Pharmaceuticals, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi, Johnson & Johnson Services, Inc., and Pfizer, Inc. are amongst the prominent players in the hospital infection therapeutics market.
 
Major geographies analyzed under this research report are: 
  • North America 
  • Europe
  • Asia  Pacific
  • Rest of the World 
This report gives you access to decisive data such as:
  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for the coming years 
Key highlights of this report:
  • Overview of key market forces propelling and restraining market growth 
  • Up-to-date analyses of market trends and technological improvements
  • Pin-point analyses of market competition dynamics to offer you a competitive edge
  • An analysis of strategies of major competitors 
  • An array of graphics and SWOT analysis of major industry segments 
  • Detailed analyses of industry trends
  • A well-defined technological growth map with an impact-analysis 
  • Offers a clear understanding of the competitive landscape and key product segments


 
 
Back To Top